AN OUTCOMES MODEL ASSESSING THE IMPACT OF EARLY DISCONTINUATION OF EVEROLIMUS (EVE) DUE TO STOMATITIS ON HEALTH AND PATIENT-REPORTED OUTCOMES IN POSTMENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED BREAST CANCER (ABC) RECEIVING EVEROLIMUS-EXEMESTANE COMBINATION THERAPY (EVE-EXE)

Toram N.; Mahjoubi R.; Tang D.

首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >AN OUTCOMES MODEL ASSESSING THE IMPACT OF EARLY DISCONTINUATION OF EVEROLIMUS (EVE) DUE TO STOMATITIS ON HEALTH AND PATIENT-REPORTED OUTCOMES IN POSTMENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED BREAST CANCER (ABC) RECEIVING EVEROLIMUS-EXEMESTANE COMBINATION THERAPY (EVE-EXE)

【24h】

AN OUTCOMES MODEL ASSESSING THE IMPACT OF EARLY DISCONTINUATION OF EVEROLIMUS (EVE) DUE TO STOMATITIS ON HEALTH AND PATIENT-REPORTED OUTCOMES IN POSTMENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED BREAST CANCER (ABC) RECEIVING EVEROLIMUS-EXEMESTANE COMBINATION THERAPY (EVE-EXE)

机译：一种结果模型，评估everolimus（前夕）早期停药的影响因患有HR + / Her2晚期乳腺癌（ABC）的绝经后妇女的健康和患者报告的结果（ABC）接受艾莫莫司 - exemestane组合治疗（EVE-EXE）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research》 |2017年第5期|共1页
作者
Toram N.; Mahjoubi R.; Tang D.;
展开▼
作者单位

Novartis Healthcare Pvt Ltd Hyderabad Andhra Pradesh India;

Nova Pharmaceut Corp E Hanover NJ USA;

Nova Pharmaceut Corp E Hanover NJ USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词

相似文献

外文文献
专利

1. AN OUTCOMES MODEL ASSESSING THE IMPACT OF EARLY DISCONTINUATION OF EVEROLIMUS (EVE) DUE TO STOMATITIS ON HEALTH AND PATIENT-REPORTED OUTCOMES IN POSTMENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED BREAST CANCER (ABC) RECEIVING EVEROLIMUS-EXEMESTANE COMBINATION THERAPY (EVE-EXE) [J] . Toram N., Mahjoubi R., Tang D. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：一种结果模型，评估everolimus（前夕）早期停药的影响因患有HR + / Her2晚期乳腺癌（ABC）的绝经后妇女的健康和患者报告的结果（ABC）接受艾莫莫司 - exemestane组合治疗（EVE-EXE）
2. PATIENT-REPORTED OUTCOMES (PRO) IN PATIENTS (PTS) WITH HER2-ADVANCED BREAST CANCER (ABC) RECEIVING TALAZOPARIB (TALA) VS PHYSICIAN'S CHOICE CHEMOTHERAPY (PCT): A FOCUS ON EMBRACA GERMLINE BRCA1 AND BRCA2 MUTATION (GBRCA1/2M) SUBGROUPS [J] . Goncalves Anthony, Quek Ruben G. W., Bhattacharyya Helen, The Breast : . 2019,第Suppla2期

机译：患者（PTS）患者（PTS）患者（PTS）患者（ABC）接受Talazoparib（TALA）VS Physisian的选择化疗（PCT）：专注于Hotmaca Germline BRCA1和BRCA2突变（GBRCA1 / 2M）亚组
3. PATIENT-REPORTED OUTCOMES (PROS) IN PATIENTS (PTS) WITH ADVANCED BREAST CANCER (ABC) AND A GERMLINE BRCA1/2 MUTATION (GBRCAM) RECEIVING TALAZOPARIB (TALA) VS PHYSICIAN'S CHOICE CHEMOTHERAPY TREATMENT (PCT): A FOCUS ON THE EMBRACA HR+/HER2-SUBPOPULATION [J] . Hurvitz Sara A., Quek Ruben G. W., Ettl Johannes, The Breast : . 2018,第Suppla1期

机译：患者（PTS）的患者报告的结果（PRO），具有晚期乳腺癌（ABC）和种系BRCA1 / 2突变（GBRCAM）接受TALAZOPARIB（TALA）VS Physisian的选择化疗治疗（PCT）：专注于HERACA HR + / HER2-亚居民
4. Effects of primary prophylaxis of neutropenia on outcomes, utilization and expenditures for elderly breast cancer patients receiving chemotherapy. [D] . Rajan, Suja S. 2009

机译：一级预防中性粒细胞减少对老年接受化疗的乳腺癌患者的结局，利用和支出的影响。
5. Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries [O] . Alison Davie, Gebra Cuyun Carter, Alex Rider, 2020

机译：现实世界患者报告的妇女的结果接受初始内分泌疗法的HR + / HER2晚期乳腺癌在五个欧洲国家
6. Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries [O] . Alison Davie, Gebra Cuyun Carter, Alex Rider, 2020

机译：现实世界患者报告的妇女的结果接受初始内分泌疗法的HR + / HER2晚期乳腺癌在五个欧洲国家

AN OUTCOMES MODEL ASSESSING THE IMPACT OF EARLY DISCONTINUATION OF EVEROLIMUS (EVE) DUE TO STOMATITIS ON HEALTH AND PATIENT-REPORTED OUTCOMES IN POSTMENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED BREAST CANCER (ABC) RECEIVING EVEROLIMUS-EXEMESTANE COMBINATION THERAPY (EVE-EXE)

著录项

相似文献

相关主题

期刊订阅